title: Why switch from protease inhibitors (PI) to non-nucleoside reverse transcriptase inhibitors (NNRTI)?
authors.affiliation: Kobler Centre, Chelsea and Westminster Hospital, London, UK.
authors.forename: A L
authors.initials: AL
authors.lastname: Pozniak
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects / Q000502:physiology; D006801:Humans; D011480:Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D019380:Anti-HIV Agents; D011480:Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors